CD19/BCMA CAR-T cell therapy showed promising results in a phase 2 trial (ChiCTR-OIC-17011272, 62 participants), with CR or better outcomes observed in 60% of patients, CRS in 95% of patients, of which 10% were grade 3 or higher, and neurotoxic events in 11% of patients, of which 3% were grade 3 or higher (CRS, Lee 2014 criteria; other adverse events, CTCAE v4.03) [171]. Here, CD19 is linked to congenital rubella syndrome.